Another Biotech Steals The Show Following Major Clinical Data Release

By: Dylan Sikes – AllPennyStocks.com News

Wednesday, March 20, 2024

There was some pretty substantial news coming out of Dallas, TX this morning after a biotech company shared initial clinical data from the first pediatric patient from the REVEAL Phase ½ adolescent and adult trial of TSHA-102, an investigational gene therapy, in adult females with Rett syndrome, according to a press release.

This news comes in conjunction with JMP Securities analyst Silvan Tuerkcan reiterated his outperform rating while maintaining a $5.00 price target. Seeing that shares of Taysha Gene Therapies Inc. (Nasdaq:TSHA) closed at just $2.25/share yesterday, it’s no wonder that traders were excited to get their hands on a position of their own. Shares of this biotech reached up to $3.1762/share (+41.16%) at the early session high.

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.

Copyright © 2024 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.